Is EDAP a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

801 people get EDAP articles and Market Currents by email alert.

Get email alerts on EDAP »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

EDAP Prepares Prostate Cancer System For U.S. Market
Brian L. Wilson • Tue, Feb 26 • 12 Comments
EDAP: The 'Holy Grail' In The Fight Against Prostate Cancer
Biotech Breakthroughs • Mon, Feb 25 • 22 Comments
EDAP: An Undervalued Company With An Alternative Treatment For Prostate Cancer
Scott Matusow • Thu, Jan 3 • 17 Comments
EDAP: Now A Compelling Prostate Cancer Play
Jessica King Holden • Tue, Apr 17, 2012 • 4 Comments
EDAP's Move Likely Short Lived
Jessica King Holden • Tue, Jan 24, 2012 • 8 Comments

To learn more about Seeking Alpha Pro, click here.

VIX - Options Volatility And Market Sonar: Thursday Recap
Erick McKitterick • Thu, Mar 7 • 17 Comments
Thursday's Small Cap Biotech Catalyst Watch List
Scott Matusow • Thu, Jan 3 • 16 Comments
Opportunities In Foreign Healthcare Equipment And Services Provider Stocks
David Hunkar • Mon, Oct 3, 2011
Movement in Medical Device Small Caps
M. E. Garza • Fri, Nov 12, 2010 • 5 Comments
The Complete List of French ADR Stocks
David Hunkar • Mon, Nov 9, 2009 • 2 Comments
12 European ADRs Up More than 100% YTD
David Hunkar • Mon, Oct 26, 2009
Four European Healthcare ADRs
David Hunkar • Wed, Jun 10, 2009 • 3 Comments

Edap TMS CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 16
EDAP TMS's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Apr 2
EDAP TMS's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 21, 2012 • 1 Comment
EDAP TMS SA Q3 2008 Earnings Call Transcript
Thu, Nov 20, 2008
EDAP TMS S.A. Wall Street Analyst Forum Presentation Transcript
Tue, Sep 9, 2008
EDAP TMS S.A. Q2 2008 Earnings Call Transcript
Sun, Aug 24, 2008

EDAP Granted European Market Clearance for Focal.One(R)

GlobeNewswire (Tue, 9:01AM)
EDAP Fully Redeems $8.0 Million Long-Term Debt

GlobeNewswire (Fri, 9:00AM)
EDAP Significantly Strengthens Financial Profile

GlobeNewswire (May 29, 2013)
EDAP to Raise $12 Million in Registered Direct Offering

GlobeNewswire (May 21, 2013)
EDAP's Ablatherm-HIFU Demonstrates Long Term Efficacy, Durability and Reproducibility With Prospective Fourteen -Year Study

GlobeNewswire (May 20, 2013)
EDAP Reports 23% Increase in First Quarter 2013 Revenues

GlobeNewswire (May 16, 2013)
EDAP's Ablatherm-HIFU Receives Two Best Poster Awards at 2013 American Urological Association Annual Meeting

GlobeNewswire (May 14, 2013)
EDAP Schedules Webcast and Conference Call for First Quarter 2013 Results

GlobeNewswire (May 13, 2013)
EDAP Outlines Significant Participation at 2013 American Urological Association Annual Meeting

GlobeNewswire (May 1, 2013)
EDAP Announces 23% First Quarter 2013 Revenue Growth

GlobeNewswire (Apr 11, 2013)
EDAP Reports Fourth Quarter 2012 and Full Year Results

GlobeNewswire (Apr 2, 2013)
EDAP Receives U.S. FDA Filing Acceptance of Pre-Market Approval Application

GlobeNewswire (Mar 28, 2013)
EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cancer

GlobeNewswire (Mar 14, 2013)
EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2012 Results

GlobeNewswire (Mar 12, 2013)
EDAP Receives U.S. FDA Administrative Acceptance Review Notification for Ablatherm(R)-HIFU Pre-Market Approval Application

GlobeNewswire (Mar 7, 2013)
EDAP's Ablatherm-HIFU Offers Reliable Therapy for Localized Prostate Cancer

GlobeNewswire (Feb 22, 2013)
EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period

GlobeNewswire (Feb 8, 2013)
EDAP Submits U.S. FDA Pre-Market Approval Application for Ablatherm(R)-HIFU for Treatment of Low Risk, Localized Prostate Cancer

GlobeNewswire (Feb 1, 2013)
EDAP Reports 25% Year-Over-Year Revenue Growth for Fourth Quarter 2012

GlobeNewswire (Jan 22, 2013)
EDAP Reports Third Quarter 2012 Results

GlobeNewswire (Nov 21, 2012)

EDAP vs. ETF Alternatives

Company Description

Currently, there's no company description for EDAP.

Sector: Healthcare

Industry: Medical Appliances & Equipment

Country: France

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, June 19, 5:30 PM After-hours top gainers, as of 5:15 p.m.: FNSR +10%. GME +9%. HW +7%. EDAP +6%. NOK +5%.
After-hours top losers: GASX -9%. ZIXI -7%. SCS -4%. QAI -2%. GLW -2%. 2 Comments [On the Move]
Monday, June 17, 3:16 PM EDAP (EDAP -12.4%) slides again today after the therapeutic ultrasound provider reported on Friday the full redemption of its $8M in outstanding long-term debt by using a portion of the net proceeds from the $12M private placement executed on May 28. Comment! [On the Move]
Monday, June 17, 12:45 PM Midday top 10 gainers: FRO +24%. KNDI +23%. IGLD +20%. HOTR +17%. LIVE +16%. DQ +15%. BIOL +14%. HAST +14%. GNK +13%. CLFD +13%.
Midday top 10 Losers: FOLD -25%. ORMP -15%. SGOC -12%. EDAP -11%. AXU -10%. BLIN -9%. CERE -9%. RVLT -9%. TEX -9%. PXLW -9%. Comment! [On the Move]
Friday, June 14, 3:43 PM EDAP (EDAP -12%) says it's fully redeemed $8M of its outstanding long-term debt by using a portion of the net proceeds from the $12M private placement executed on May 28. EDAP CEO Marc Oczachowski said the subsequent elimination of the 9% annual interest rate and removal of the obligation ahead of its June 2014 maturity has resulted in a "successfully streamlined" balance sheet. 2 Comments [On the Move, Healthcare]
Friday, June 14, 12:45 PM Midday top 10 gainers: BCSB +31%. RH +18%. CDXS +17%. SGOC +17%. BLIN +16%. LGL +15%. RVLT +13%. GRPN +13%. UNXL +12%. FMAR +12%.
Midday top 10 Losers: CEMP -14%. OSH -14%. UNTK -13%. UPI -12%. EDAP -12%. CPST -11%. OCLS -11%. CLSN -10%. AMSC -9%. ACH -9%. Comment! [On the Move]
Tuesday, May 21, 10:46 AM Edap (EDAP -8.3%) plunges after announcing a registered direct placement of $12M in shares at $4 each with attached warrants for up to 1.5M additional shares at an exercise price of $4.25. Today's losses erase strong gains posted Monday on the back of positive data from a long-term study of HIFU therapy. (PR) Comment! [Healthcare, On the Move]
Monday, May 20, 11:48 AM Edap (EDAP +5.3%) posts solid gains after saying minimally invasive, high-intensity focused ultrasound (HIFU) therapy demonstrates "encouraging cancer-specific survival rates in patients with localized prostate cancer." The company cites data culled from a large, long-term study of "mobility and oncologic outcomes" conducted by two doctors at Edouard Herriot Hospital in France. (PR) Comment! [Healthcare, On the Move]
Thursday, May 16, 11:45 AM Edap (EDAP -3.5%) falls after missing the one available analyst EPS estimate, although revenues beat by a slim margin and rise 23% Y/Y on "strong demand for [the company's] innovative lithotripsy product range in key global markets." CEO Marc Oczachowski says the "FDA process for Ablatherm-HIFU is on track." Profit margins fall 220 basis points Y/Y on a negative yen impact and operating expenses increase 9.7% on "continued regulatory expenses associated with the PMA filing for Ablatherm-HIFU, as well as sales and marketing investments." (PR) 5 Comments [Healthcare, Earnings, On the Move]
Thursday, May 16, 11:32 AM EDAP (EDAP): Q1 EPS of -€0.21 or -$0.27 misses by $0.22. Revenue of €5.9M or $7.8M (+23% Y/Y) beats by $0.15M. (PR) Comment! [Healthcare, Earnings]
Thursday, April 11, 8:49 AM Edap (EDAP) releases preliminary Q1 top line results of $7.8M, representing a 23% Y/Y increase — the one available analyst estimate has revenue at $7.65M for Q1. Comment!
Tuesday, April 2, 2:53 PM Shares of Edap (EDAP -5.2%) take a hit after its Q4 missed on top line estimates. Earlier today the company reported a loss of €0.06 or $0.08 per share, in line with the Street consensus for a loss of $0.08 loss per share. Revenues were €9.4M, or $12.3M, slightly beating estimates of $12.15M. In the same period last year, the company reported an EPS loss of €0.04 or $0.05 on revenues of €7.5M or $10.1M. 1 Comment [Earnings, Healthcare, On the Move]
Tuesday, April 2, 7:26 AM EDAP (EDAP): Q4 EPS of -EUR0.06. Revenue of $12.3M (+25.3% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 28, 11:51 AM Edap (EDAP +3.4%) gains after saying the FDA has given the thumbs-up on a pre-market approval application for its Ablatherm Integrated Imaging HIFU device, a high-intensity utrasound treatment for low-risk, localized prostate cancer. 1 Comment [Healthcare, Global & FX, On the Move]
Thursday, March 7, 9:36 AM The FDA accepts Edap's (EDAP +9.5%) pre-market approval application for its ultrasound device for treating low-risk, localized prostate cancer. The next step for the product, which is called the Ablatherm Integrated Imaging HIFU (High Intensity Focused Ultrasound), is the filing review. Both assessments look at the completeness of the application and not the clinical outcomes of the study. (PR) Comment! [Healthcare, On the Move]
Thursday, March 7, 9:10 AM Premarket gainers: HIMX +36%. NQ +17%. CIEN +15%. MTSL +12%. FNSR +9%. HZNP +8%. EDAP +8%. WFR +7%. DANG +6%. INFN +6%. JDSU +6%. INVE +6%. MLNX +5%.
Losers: JRCC -14%. AV -11%. SCTY -8%. PETM -8%. DRYS -7%. NBG -5%. Comment! [On the Move]
Monday, February 25, 3:45 PM ADR's of Edap TMS (EDAP +17.8%) jump today on the back of a postitive article in Seeking Alpha, calling it the 'holy grail' in the fight against prostate cancer. Its recent disclosure of test data on its Ablatherm-HIFU - which uses High-Intensity Focused Ultrasound to eviscerate localized prostate cancer - shows it's testing progress has advanced well beyond the stage of laboratories and mice, and is highly likely to receive FDA approval. Comment! [Healthcare, Global & FX, On the Move]

Robbster
$EDAP +24% since purchase, see more upside, holding...
Mar 12, 10:18 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$EDAP - $3.56. Alerted via article on Jan, 3rd @ $2.13 @ http://seekingalpha.com/a/neqx
Feb 5, 9:54 AM
Reply (1)

• !Report Abuse
View all 1 replies
keiithc71: This was an awesome pick I wish I pulled the trigger on that. I went with PATH instead. Still made profit but EDAP would have been much more
Feb 6, 1:10 AM
• !Report Abuse
Add a reply...

140 characters

Robbster
Interesting bio catalyst play in $EDAP. Thermal therapy for prostate cancer approved in EU, positive clinical results, US approv. next...
Jan 5, 11:16 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
Zooming: EDAP up 75% since last week to $4.43. Up 8% today on 5x vol. Recent heavy accumulation indicates institutional buying. Thin options
11/17/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

nobashing
Advice to EDAP - Some news will help to clear uncertanty among the investos regarding the direction company is heading.HIFU approval may be
11/5/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

JasonGordon
$BEE, $EDAP, $WAVE, $MESA, $MPG, $CVM, and $FBC all broke out of symmetrical triangles/bullish pennants recently on convincing volume. =long
10/18/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
$EDAP - $3.56. Alerted via article on Jan, 3rd @ $2.13 @ http://seekingalpha.com/a/neqx
Feb 5, 9:54 AM
Reply (1)

• !Report Abuse
View all 1 replies
keiithc71: This was an awesome pick I wish I pulled the trigger on that. I went with PATH instead. Still made profit but EDAP would have been much more
Feb 6, 1:10 AM
• !Report Abuse
Add a reply...

140 characters

EDAP EDAP TMS S.A.

EDAP

EDAP TMS S.A.